Press Resease

Hemophilia Treatment Drugs Market - Global Industry Analysis

Hemophilia Treatment Drugs Market by Product Type (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Desmopressin, and Antifibrinolytic Agents), by Disease Type (Hemophilia A, Hemophilia B, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce) - Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024

Published Date: 04-Jul-2018 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3187 Status : Published

Global hemophilia treatment drugs market expected to generate revenue of around USD 25.61 billion by the end of 2024, growing at a CAGR of around 5.7% between 2017 and 2024. Hemophilia is a genetic disorder in which the blood clotting factors are reduced; this hampers the function of blood clotting and leads to abnormal internal and external bleeding after any type of injuries.

Description

The report covers forecast and analysis for the hemophilia treatment drugs market on a global and regional level. The study provides historical data from 2015 to 2017 along with the forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the hemophilia treatment drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the hemophilia treatment drugs market on a global level.

In order to give the users of this report a comprehensive view on the hemophilia treatment drugs market, we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Hemophilia Treatment Drugs Market

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, product and regional expansion of major participants involved in the market.

The study provides a decisive view on the hemophilia treatment drugs market by segmenting it on the basis of product type, disease type, distribution channel, and region. All the segments have been analyzed based on present and the future trends and the market is estimated from 2018 to 2024. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further categorization into major countries including the U.S., the UK, Germany, France, China, Japan, India, Brazil, etc. This segmentation includes demand for hemophilia treatment drugs market based on all segments in all the regions and countries.

The report also includes detailed profiles of end players such as Shire Plc., Novo Nordisk A/S, Pfizer, Bayer AG, CSL Ltd., Biogen, and others.

This report segments the global hemophilia treatment drugs market as follows:

Global Hemophilia Treatment Drugs Market: Product Type Segment Analysis

  • Recombinant Coagulation Factor Concentrates
  • Plasma Derived Coagulation Factor Concentrates
  • Desmopressin
  • Antifibrinolytic Agents

Global Hemophilia Treatment Drugs Market: Disease Type Segment Analysis

  • Hemophilia A
  • Hemophilia B
  • Others

Global Hemophilia Treatment Drugs Market: Distribution Channel Segment Analysis

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Global Hemophilia Treatment Drugs Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global hemophilia treatment drugs market, 2015 - 2024 (USD Billion)
    • 2.2. Global hemophilia treatment drugs market: Snapshot
  •  
  • Chapter 3. Hemophilia Treatment Drugs Market - Market Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global hemophilia treatment drugs market drivers: Impact analysis
      • 3.2.2. Increasing prevalence of bleeding disorders
    • 3.3. Market Restraints
      • 3.3.1. Global hemophilia treatment drugs market restraints: Impact analysis
      • 3.3.2. Inadequate trough levels
    • 3.4. Opportunities
      • 3.4.1. Development of new drugs
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by product type segment
      • 3.6.2. Market attractiveness analysis, by disease type segment
      • 3.6.3. Market attractiveness analysis, by distribution channel segment
      • 3.6.4. Market attractiveness analysis, by regional segment
  •  
  • Chapter 4. Global Hemophilia Treatment Drugs Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global hemophilia treatment drugs market: company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New product launch
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  •  
  • Chapter 5. Global Hemophilia Treatment Drugs Market - Product Type Segment Analysis
    • 5.1. Global hemophilia treatment drugs market: Product Type overview
      • 5.1.1. Global hemophilia treatment drugs market revenue share, by product type, 2017 and 2024
    • 5.2. Recombinant Coagulation Factor Concentrates
      • 5.2.1. Global hemophilia treatment drugs market for recombinant coagulation factor concentrates, 2015 - 2024 (USD Billion)
    • 5.3. Plasma Derived Coagulation Factor Concentrates
      • 5.3.1. Global hemophilia treatment drugs market for plasma derived coagulation factor concentrates, 2015 - 2024 (USD Billion)
    • 5.4. Desmopressin
      • 5.4.1. Global hemophilia treatment drugs market for desmopressin, 2015 - 2024 (USD Billion)
    • 5.5. Antifibrinolytic Agents
      • 5.5.1. Global hemophilia treatment drugs market for antifibrinolytic agents, 2015 - 2024 (USD Billion)
  •  
  • Chapter 6. Global Hemophilia Treatment Drugs Market - Disease Type Segment Analysis
    • 6.1. Global hemophilia treatment drugs market: Disease type overview
      • 6.1.1. Global hemophilia treatment drugs market revenue share, by disease type, 2017 and 2024
    • 6.2. Hemophilia A
      • 6.2.1. Global hemophilia treatment drugs market by hemophilia A, 2015 - 2024 (USD Billion)
    • 6.3. Hemophilia B
      • 6.3.1. Global hemophilia treatment drugs market by hemophilia B, 2015 - 2024 (USD Billion)
    • 6.4. Others
      • 6.4.1. Global hemophilia treatment drugs market by other disease types, 2015 - 2024 (USD Billion)
  •  
  • Chapter 7. Global Hemophilia Treatment Drugs Market - Distribution Channel Segment Analysis
    • 7.1. Global hemophilia treatment drugs market: Distribution channel overview
      • 7.1.1. Global hemophilia treatment drugs market revenue share, by distribution channel, 2017 and 2024
    • 7.2. Hospital Pharmacies
      • 7.2.1. Global hemophilia treatment drugs market for hospital pharmacies, 2015 - 2024 (USD Billion)
    • 7.3. Retail Pharmacies
      • 7.3.1. Global hemophilia treatment drugs market for retail pharmacies, 2015 - 2024 (USD Billion)
    • 7.4. E-Commerce
      • 7.4.1. Global hemophilia treatment drugs market for e-commerce, 2015 - 2024 (USD Billion)
  •  
  • Chapter 8. Global Hemophilia Treatment Drugs Market - Regional Segment Analysis
    • 8.1. Global hemophilia treatment drugs market: Regional overview
      • 8.1.1. Global hemophilia treatment drugs market revenue share, by region, 2017 and 2024
    • 8.2. North America
      • 8.2.1. North America hemophilia treatment drugs market, 2015 - 2024 (USD Billion)
      • 8.2.2. North America hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
      • 8.2.3. North America hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
      • 8.2.4. North America hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
      • 8.2.5. U.S.
        • 8.2.5.1. U.S. hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
        • 8.2.5.2. U.S. hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
        • 8.2.5.3. U.S. hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
        • 8.2.6.2. Rest of North America hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
        • 8.2.6.3. Rest of North America hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
    • 8.3. Europe
      • 8.3.1. Europe hemophilia treatment drugs market, 2015 - 2024 (USD Billion)
      • 8.3.2. Europe hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
      • 8.3.3. Europe hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
      • 8.3.4. Europe hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
      • 8.3.5. UK
        • 8.3.5.1. UK hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
        • 8.3.5.2. UK hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
        • 8.3.5.3. UK hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
      • 8.3.6. Germany
        • 8.3.6.1. Germany hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
        • 8.3.6.2. Germany hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
        • 8.3.6.3. Germany hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
      • 8.3.7. France
        • 8.3.7.1. France hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
        • 8.3.7.2. France hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
        • 8.3.7.3. France hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of Europe hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
        • 8.3.8.2. Rest of Europe hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
        • 8.3.8.3. Rest of Europe hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific hemophilia treatment drugs market, 2015 - 2024 (USD Billion)
      • 8.4.2. Asia Pacific hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
      • 8.4.3. Asia Pacific hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
      • 8.4.4. Asia Pacific hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
      • 8.4.5. China
        • 8.4.5.1. China hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
        • 8.4.5.2. China hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
        • 8.4.5.3. China hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
      • 8.4.6. Japan
        • 8.4.6.1. Japan hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
        • 8.4.6.2. Japan hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
        • 8.4.6.3. Japan hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
      • 8.4.7. India
        • 8.4.7.1. India hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
        • 8.4.7.2. India hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
        • 8.4.7.3. India hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
        • 8.4.8.2. Rest of Asia Pacific hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
        • 8.4.8.3. Rest of Asia Pacific hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
    • 8.5. Latin America
      • 8.5.1. Latin America hemophilia treatment drugs market, 2015 - 2024 (USD Billion)
      • 8.5.2. Latin America hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
      • 8.5.3. Latin America hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
      • 8.5.4. Latin America hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
        • 8.5.5.2. Brazil hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
        • 8.5.5.3. Brazil hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
      • 8.5.6. Rest of Latin America
        • 8.5.6.1. Rest of Latin America hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
        • 8.5.6.2. Rest of Latin America hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
        • 8.5.6.3. Rest of Latin America hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
    • 8.6. Middle East and Africa
      • 8.6.1. Middle East and Africa hemophilia treatment drugs market, 2015 - 2024 (USD Billion)
      • 8.6.2. Middle East and Africa hemophilia treatment drugs market revenue, by product type, 2015 - 2024 (USD Billion)
      • 8.6.3. Middle East and Africa hemophilia treatment drugs market revenue, by disease type, 2015 - 2024 (USD Billion)
      • 8.6.4. Middle East and Africa hemophilia treatment drugs market revenue, by distribution channel, 2015 - 2024 (USD Billion)
  •  
  • Chapter 9. Company Profile
    • 9.1. Shire PLC
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. Novo Nordisk A/S
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. Pfizer
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. Bayer AG
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. CSL Ltd.
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Developments
    • 9.6. Biogen
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Developments

List of Figures 

1. Market research process
2. Market research methodology
3. Global hemophilia treatment drugs market revenue, 2015 – 2024 (USD Billion) 
4. Porter’s five forces analysis
5. Hemophilia treatment drugs market attractiveness analysis, by product type segment
6. Hemophilia treatment drugs market attractiveness analysis, by disease type segment
7. Hemophilia treatment drugs market attractiveness analysis, by distribution channel segment
8. Hemophilia treatment drugs market: market attractiveness analysis, by regional segment
9. Company market share analysis, 2017 
10. Global hemophilia treatment drugs market revenue share by product type, 2017 and 2024
11. Global hemophilia treatment drugs market for recombinant coagulation factor concentrates, 2015 – 2024 (USD Billion)
12. Global hemophilia treatment drugs market for plasma derived coagulation factor concentrates, 2015 – 2024 (USD Billion)
13. Global hemophilia treatment drugs market for desmopressin, 2015 – 2024 (USD Billion)
14. Global hemophilia treatment drugs market for antifibrinolytic agents, 2015 – 2024 (USD Billion)
15. Global hemophilia treatment drugs market revenue share by disease type, 2017 and 2024
16. Global hemophilia treatment drugs market by hemophilia A, 2015 – 2024 (USD Billion)
17. Global hemophilia treatment drugs market by hemophilia B, 2015 – 2024 (USD Billion) 
18. Global hemophilia treatment drugs market revenue share by distribution channel, 2017 and 2024
19. Global hemophilia treatment drugs market for hospital pharmacies, 2015 – 2024 (USD Billion)
20. Global hemophilia treatment drugs market for retail pharmacies, 2015 – 2024 (USD Billion)
21. Global hemophilia treatment drugs market for e-commerce, 2015 – 2024 (USD Billion)
22. North America hemophilia treatment drugs market, 2015-2024 (USD Billion)
23. Europe hemophilia treatment drugs market, 2015-2024 (USD Billion)
24. Asia Pacific hemophilia treatment drugs market, 2015-2024 (USD Billion)
25. Latin America hemophilia treatment drugs market, 2015-2024 (USD Billion)
26. The Middle East and Africa hemophilia treatment drugs market, 2015-2024 (USD Billion)


List of Tables

1. Global hemophilia treatment drugs market: Market Snapshot                               
2. Drivers of global hemophilia treatment drugs market: Impact analysis 
3. Restraints of global hemophilia treatment drugs market: Impact analysis  
4. North America hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
5. North America hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
6. North America hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
7. U.S. hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
8. U.S. hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
9. U.S. hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
10. Rest of North America hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
11. Rest of North America hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
12. Rest of North America hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
13. Europe hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
14. Europe hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
15. Europe hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
16. UK hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
17. UK hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
18. UK hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
19. Germany hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
20. Germany hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
21. Germany hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
22. France hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
23. France hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
24. France hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
25. Rest of Europe hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
26. Rest of Europe hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
27. Rest of Europe hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
28. Asia Pacific hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
29. Asia Pacific hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
30. Asia Pacific hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
31. China hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
32. China hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
33. China hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
34. Japan hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
35. Japan hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
36. Japan hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
37. India hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
38. India hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
39. India hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
40. Rest of Asia Pacific hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
41. Rest of Asia Pacific hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
42. Rest of Asia Pacific hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
43. Latin America hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
44. Latin America hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
45. Latin America hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
46. Brazil hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
47. Brazil hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
48. Brazil hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
49. Rest of Latin America hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
50. Rest of Latin America hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
51. Rest of Latin America hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)
52. Middle East and Africa hemophilia treatment drugs market revenue, by product type, 2015 – 2024 (USD Billion)
53. Middle East and Africa hemophilia treatment drugs market revenue, by disease type, 2015 – 2024 (USD Billion)
54. The Middle East and Africa hemophilia treatment drugs market revenue, by distribution channel, 2015 – 2024 (USD Billion)

Methodology

Free Analysis

Hemophilia is a rare bleeding disorder which is inherited from parents that cause abnormal or exaggerated bleeding and poor blood clotting. Hemophilia A, B, C and acquired hemophilia are the types of hemophilia disorders which are generally seen in human beings. Hemophilia is inherited through the X-linked recessive genetic pattern. Treatment of hemophilia includes replacement of the specific clotting factor that is reduced in the genes.

According to the estimates of National Hemophilia Foundation (U.S.), there are over 4 million people suffering from hemophilia. Approximately only 25% of these patients get proper treatment for hemophilia. Increase in the number of hemophilia patients and the required treatments acts as the main drivers for the growth of global hemophilia treatment drugs market. Growing awareness about the disease, increase in government assistance, technological advancements in the improvement of drugs, and improving regulatory framework fuels the growth of the global hemophilia treatment drugs market. Counterfeit drugs and poor healthcare systems in developing and under-developed regions act as the restraints for the growth of the market.

The product type segment is divided into recombinant coagulation factor concentrate (RCFC), desmopressin, an antifibrinolytic agent, and plasma derived coagulation factor concentrate (PDCFC). The RCFC segment is anticipated to dominate the global market of hemophilia treatment drugs as it exhibits low risk of blood-related infections. The PDCFC is also expected to show a significant growth. Plasma derivatives are fractions that are isolated from human blood which contains three main components namely immunoglobin, albumin, and clotting factors. A number of countries have attempted to implement local collection and fractionation programmers, due to which there is increasing demand for this plasma derived factors which drives the growth of this segment.

Global Hemophilia Treatment Drugs Market

The disease type segment includes hemophilia B, hemophilia A, and others. Hemophilia A is caused when there is lack of factor VIII in blood. In 2016, over 149,800 patients were suffering from hemophilia A. This number is anticipated to increase in the near future. Due to this, the hemophilia A segment is expected to dominate the disease type segment in the forecast period.

Based on distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and e-commerce. The hospital pharmacies segment is anticipated to lead the global hemophilia treatment drugs market. The e-commerce segment is anticipated to show rapid growth due to increase in the use of internet services.

The growing awareness about the number of treatments available for hemophilia has helped North America to continue its supremacy in global hemophilia treatment drugs market. Asia Pacific is expected to show the highest CAGR owing to the dynamic shift in the consumption pattern of consumers due to the changing lifestyles in this region.

Some of the key players in the global hemophilia treatment drugs market are Shire Plc., Novo Nordisk A/S, Pfizer, Bayer AG, CSL Ltd., Biogen, and others. Some players are engaged in expanding their presence in various regions of Asia Pacific such as in China, Japan, and South Korea as there has been a rapid increase in demand for treatment drugs.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed